Interestingly, triple-negative breast cancers, which share a similar molecular and histopathological profile with BRCA1-mutated breast cancers, have also been found to be sensitive to gemcitabine [49,53]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.